Polaryx Therapeutics names Will Charlton chief medical officer ahead of Phase 2 trial

Polaryx Therapeutics, Inc. (Nasdaq: PLYX) disclosed in an 8-K filed September 1, 2026 that on August 27, 2026, the company appointed Will Charlton, M.D., M.A.S. as its Chief Medical Officer, effective September 1, 2026.¹

Charlton's background includes work across multiple biotech companies. From March 2025 to June 2026, he served as Senior Vice President of Clinical Development for Skeletal Dysplasia at Tyra Biosciences, where he guided a Phase 2 rare disease trial program to key milestones and built out a clinical development plan spanning multiple indications.¹ Before that, he was Chief Medical Officer at Spruce Biosciences from March 2022 to January 2025, where he reworked the company's congenital adrenal hyperplasia program to focus on pediatric patients and oversaw dose-finding and registrational-stage studies.¹ Earlier, from November 2020 to March 2022, he was Vice President of Clinical Development at 89bio, leading clinical strategy for pegozafermin in MASH and severe hypertriglyceridemia.¹ He is a board-certified pediatric endocrinologist with more than a decade in clinical practice, and his background spans endocrinology, rare disease, growth disorders, and metabolic disease.¹

Charlton's arrival comes as Polaryx works toward its "SOTERIA" trial, a Phase 2 study of lead candidate PLX-200 in four lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. The FDA gave Polaryx a safe-to-proceed letter in October 2025, and the company intends to begin the trial in the fourth quarter of 2026, starting with U.S. sites before expanding to other countries.¹ CEO Alex Yang said the trial remains on track to start in the fourth quarter of 2026.¹